Suppr超能文献

中东地区12月龄以下婴儿功能性胃肠病诊断与管理共识声明

Middle East Consensus Statement on the Diagnosis and Management of Functional Gastrointestinal Disorders in <12 Months Old Infants.

作者信息

Vandenplas Yvan, Alturaiki Muath Abdurrahman, Al-Qabandi Wafaa, AlRefaee Fawaz, Bassil Ziad, Eid Bassam, El Beleidy Ahmed, Almehaidib Ali Ibrahim, Mouawad Pierre, Sokhn Maroun

机构信息

Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

Department of Pediatrics, King Salman Hospital, Riyadh, Saudi Arabia.

出版信息

Pediatr Gastroenterol Hepatol Nutr. 2016 Sep;19(3):153-161. doi: 10.5223/pghn.2016.19.3.153. Epub 2016 Sep 29.

Abstract

This paper covers algorithms for the management of regurgitation, constipation and infantile colic in infants. Anti-regurgitation formula may be considered in infants with troublesome regurgitation, while diagnostic investigations or drug therapy are not indicated in the absence of warning signs. Although probiotics have shown some positive evidence for the management of functional gastrointestinal disorders (FGIDs), the evidence is not strong enough to make a recommendation. A partially hydrolyzed infant formula with prebiotics and β-palmitate may be considered as a dietary intervention for functional constipation in formula fed infants. Lactulose has been shown to be effective and safe in infants younger than 6 months that are constipated. Macrogol (polyethylene glycol, PEG) is not approved for use in infants less than 6 months of age. However, PEG is preferred over lactulose in infants >6 months of age. Limited data suggests that infant formula with a partial hydrolysate, galacto-oligosaccharides/fructo-oligosaccharides, added β-palmitate may be of benefit in reducing infantile colic in formula fed infants in cases where cow's milk protein allergy (CMPA) is not suspected. Evidence suggests that the use of extensively hydrolyzed infant formula for a formula-fed baby and a cow's milk free diet for a breastfeeding mother may be beneficial to decrease infantile colic if CMPA is suspected. None of the FGIDs is a reason to stop breastfeeding.

摘要

本文涵盖了婴儿反流、便秘和婴儿腹绞痛的管理算法。对于有严重反流问题的婴儿,可考虑使用抗反流配方奶粉;而在没有警示信号的情况下,不建议进行诊断性检查或药物治疗。尽管益生菌已显示出对功能性胃肠疾病(FGIDs)管理有一些积极证据,但证据强度不足以给出推荐。含益生元及β-棕榈酸酯的部分水解婴儿配方奶粉可作为配方奶喂养婴儿功能性便秘的饮食干预措施。乳果糖已被证明对6个月以下便秘婴儿有效且安全。聚乙二醇(PEG)未被批准用于6个月以下婴儿。然而,对于6个月以上婴儿,PEG比乳果糖更受青睐。有限的数据表明,在不怀疑牛奶蛋白过敏(CMPA)的情况下,含部分水解产物、低聚半乳糖/低聚果糖、添加β-棕榈酸酯的婴儿配方奶粉可能有助于减少配方奶喂养婴儿的腹绞痛。有证据表明,如果怀疑CMPA,给配方奶喂养的婴儿使用深度水解婴儿配方奶粉以及给母乳喂养的母亲采用无牛奶饮食可能有助于减少婴儿腹绞痛。没有一种FGIDs是停止母乳喂养的理由。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f9/5061656/2dea748f87fe/pghn-19-153-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验